Induced pluripotent stem cell–derived exosomes attenuate vascular remodelling in pulmonary arterial hypertension by targeting HIF-1α and Runx2
Cardiovascular Research · 13.03.2024 · 120 (2) · 203-214
DOI: 10.1093/cvr/cvad185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 22.01.2024. Verfasst von Pei-Ling Chi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Hypertension, Pulmonary, Induced Pluripotent Stem Cells, Exosomes. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Kaohsiung Veterans General Hospital, Yen Tjing Ling Medical Foundation.
Abstract (Originalsprache)
Aims
Pulmonary arterial hypertension (PAH) is characterized by extensive pulmonary arterial remodelling. Although mesenchymal stem cell (MSC)-derived exosomes provide protective effects in PAH, MSCs exhibit limited senescence during in vitro expansion compared with the induced pluripotent stem cells (iPSCs). Moreover, the exact mechanism is not known. Methods and results In this study, we used murine iPSCs generated from mouse embryonic fibroblasts with triple factor (Oct4, Klf4, and Sox2) transduction to determine the efficacy and action mechanism of iPSC-derived exosomes (iPSC-Exo) in attenuating PAH in rats with monocrotaline (MCT)-induced pulmonary hypertension. Both early and late iPSC-Exo treatment effectively prevented the wall thickening and muscularization of pulmonary arterioles, improved the right ventricular systolic pressure, and alleviated the right ventricular hypertrophy in MCT-induced PAH rats. Pulmonary artery smooth muscle cells (PASMC) derived from MCT-treated rats (MCT-PASMC) developed more proliferative and pro-migratory phenotypes, which were attenuated by the iPSC-Exo treatment. Moreover, the proliferation and migration of MCT-PASMC were reduced by iPSC-Exo with suppression of PCNA, cyclin D1, MMP-1, and MMP-10, which are mediated via the HIF-1α and P21-activated kinase 1/AKT/Runx2 pathways.
Conclusion
IPSC-Exo are effective at reversing pulmonary hypertension by reducing pulmonary vascular remodelling and may provide an iPSC-free therapy for the treatment of PAH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Department of Critical Care Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Department of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Physical Therapy, Fooyin University, Kaohsiung, Taiwan.
ORCID-Profile: Pei-Ling Chi, Wei-Chun Huang
Förderung
- Kaohsiung Veterans General Hospital
- Yen Tjing Ling Medical Foundation
Zitieren
APA
Chi, P. L., Cheng, C. C., Wang, M. T., Liao, J. B., Kuo, S. H., Lin, K. C., Shen, M. C., & Huang, W. C. (2024). Induced pluripotent stem cell–derived exosomes attenuate vascular remodelling in pulmonary arterial hypertension by targeting HIF-1α and Runx2. Cardiovascular Research, 120(2), 203-214. https://doi.org/10.1093/cvr/cvad185
Vancouver
Chi PL, Cheng CC, Wang MT, Liao JB, Kuo SH, Lin KC, et al. Induced pluripotent stem cell–derived exosomes attenuate vascular remodelling in pulmonary arterial hypertension by targeting HIF-1α and Runx2. Cardiovascular Research. 2024;120(2):203-214. doi:10.1093/cvr/cvad185
BibTeX
@article{Chi2024,
author = {Chi, Pei-Ling and Cheng, Chin-Chang and Wang, Mei-Tzu and Liao, Jia-Bin and Kuo, Shu-Hung and Lin, Kun-Chang and Shen, Min-Ci and Huang, Wei-Chun},
title = {Induced pluripotent stem cell–derived exosomes attenuate vascular remodelling in pulmonary arterial hypertension by targeting HIF-1α and Runx2},
journal = {Cardiovascular Research},
year = {2024},
volume = {120},
number = {2},
pages = {203--214},
doi = {10.1093/cvr/cvad185}
}
EUVIMED